| Protein tyrosine phosphatase inhibitors: a patent review (2002–2011) ME Sobhia, S Paul, R Shinde, M Potluri, V Gundam, A Kaur, T Haokip Expert Opinion on Therapeutic Patents 22 (2), 125-153, 2012 | 24 | 2012 |
| Protein kinase C inhibitors: a patent review (2008–2009) ME Sobhia, BK Grewal, SP Ml, J Patel, A Kaur, T Haokip, A Kokkula Expert Opinion on Therapeutic Patents 23 (10), 1297-1315, 2013 | 22 | 2013 |
| Essential gene identification and drug target prioritization in Leishmania species MLS Paul, A Kaur, A Geete, ME Sobhia Molecular bioSystems 10 (5), 1184-1195, 2014 | 20 | 2014 |
| Protein kinase C inhibitors: a patent review (2010–present) ME Sobhia, BK Grewal, MLS Paul, J Patel, A Kaur, T Haokip, A Kokkula Expert opinion on therapeutic patents 23 (11), 1451-1468, 2013 | 16 | 2013 |
| Identification of potential ACE2-derived peptide mimetics in SARS-CoV-2 omicron variant therapeutics using computational approaches S Paul, S Nadendla, ME Sobhia The Journal of Physical Chemistry Letters 13 (32), 7420-7428, 2022 | 6 | 2022 |
| Leishmania donovani eukaryotic initiation factor 5A: Molecular characterization, localization and homology modelling studies S Singh, K Raju, D Jatekar, N Dinesh, MLSP Paul, ME Sobhia Microbial Pathogenesis 73, 37-46, 2014 | 3 | 2014 |
| Design and Development of Potent H‐ACE2 Derived Peptide Mimetics in SARS‐CoV‐2 Omicron Variant Therapeutics MLS Paul, S Nadendla, EM Sobhia | 1 | 2022 |
M Elizabeth SobhiaAssistant Professor, Department of Pharmacoinformatics, NIPER S.A.S. NagarVerified email at niper.ac.in
